SDGR vs RLAY
SDGR and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | SDGRSchrodinger, Inc. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | — | $4.16B |
| P/S | — | 270.9x |
| Revenue | $259.04M(TTM) | — |
| Revenue growth (YoY) | 23.3% | 53.4% |
| Net income | -$54.34M(TTM) | — |
| Earnings growth (YoY) | 44.8% | 18.1% |
| EPS, diluted | $-0.73(TTM) | — |
| EBIT margin | -65.2% | -1971.6% |
| ROE | -31.4% | -31.1% |
| 1y total return | +26.0% | +368.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: SDGR vs RLAY
| Metric | SDGR | RLAY |
|---|---|---|
| End value | $2.9K | $5.4K |
| Total return | -70.6% | -45.9% |
| CAGR | -18.0% | -9.5% |
| Volatility | 64.4% | 76.8% |
| Sharpe | -0.05 | 0.19 |
| Sortino | -0.08 | 0.30 |
| Max drawdown | -90.2% | -96.8% |
Based on 1549 common trading days, 2020-07-16 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)